Eli Lilly

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

eat_dis_watermelon

Not Invested

Community Contributor

Published

19 Sep 25

Updated

21 Nov 25

Views

3.9k

21 Nov

US$1,065.00

eat_dis_watermelon's Fair Value

US$1,189.18

10.4% undervalued

49.2%

7.8%

49.2%

7.8%

You can edit this narrative until Nov 22 2:50 AM. Then, changes will post as Updates.

Author's Valuation

US$1.19k10.4% undervalued

eat_dis_watermelon's Fair Value

Shared on 21 Nov 25

GLP-1 drugs part of medicare

A push to include these weight-loss drugs in Medicare could make them easier for more people to get, which may keep demand strong. Recent results also suggest growth is coming from more prescriptions rather than price hikes, with no clear signs demand is cooling.

108 views

Valuator

Company Info

Notes

eat_dis_watermelon'sFair Value

US$1.19k

10.4% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Growth p.a.

Decrease

Increase

Forecast revenue growth rate

12.41%

Historical revenue growth rate

20.77%

Pharma revenue growth rate

0.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.11%

Calculation

US$34.34b

Earnings '30

49.63x

PE Ratio '30

US$1.70t

Market Cap '30

US$1.70t

Market Cap '30

889.88m

No. shares '30

US$1.92k

Share Price '30

US$1.92k Share Price '30

Discounted to 2025 @ 10.00% p.a.

US$1.19k

Fair Value '25